

# ML221

**Catalog No: tcsc0026651**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

877636-42-5

**Formula:**

$C_{17}H_{11}N_3O_6S$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 31$  mg/mL (80.45 mM)

**Observed Molecular Weight:**


385.35

## Product Description

ML221 is a potent **apelin (APJ)** functional antagonist, inhibiting apelin-13-mediated activation of APJ, with **IC<sub>50</sub>**s of 0.70  $\mu$ M in the cAMP assay, and 1.75  $\mu$ M in the  $\beta$ -arrestin assay, and **EC<sub>80</sub>** of 10 nM in both assays.

IC50 & Target: IC50: 1.75  $\mu$ M (APJ, cell-based)<sup>[1]</sup>

**In Vitro:** ML221 is a potent apelin/APJ functional antagonist, inhibiting apelin-13-mediated activation of APJ, with IC<sub>50</sub>s of 0.70  $\mu$ M in the cAMP assay, and 1.75  $\mu$ M in the  $\beta$ -arrestin assay, and EC<sub>80</sub> of 10 nM in both assays. ML221 is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor (IC<sub>50</sub>, >79  $\mu$ M) in cells. ML221 displays limited cross reactivity against a range of GPCRs except the  $\kappa$ -opioid and benzodiazepinone receptors ([1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!